Telix Pharmaceuticals (TLX) Total Non-Current Liabilities (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Total Non-Current Liabilities for 3 consecutive years, with $517.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Total Non-Current Liabilities rose 28.06% year-over-year to $517.0 million; the TTM figure through Dec 2025 stood at $517.0 million (up 28.06% YoY), while the FY2025 annual figure was $517.0 million, up 35.21% from the prior year.
• Total Non-Current Liabilities rose to $517.0 million in Q4 2025 per TLX's latest filing, from $403.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $517.0 million in Q4 2025 and bottomed at $59.9 million in Q4 2023.
• Historically, Total Non-Current Liabilities has averaged $326.9 million across 3 years, with a median of $403.7 million in 2024.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities jumped 574.17% — and 2025, when it increased 28.06%.
• Telix Pharmaceuticals' Total Non-Current Liabilities stood at $59.9 million in 2023, then surged by 574.17% to $403.7 million in 2024, then climbed by 28.06% to $517.0 million in 2025.
• Business Quant data shows TLX's Total Non-Current Liabilities at $517.0 million in Q4 2025, $403.7 million in Q4 2024, and $59.9 million in Q4 2023.